BRAF and pancreatic adenocarcinoma: Here, we add a case to the growing literature describing an elderly patient with advanced pancreatic adenocarcinoma harboring a BRAF V600E mutation who received low-dose dabrafenib combined with trametinib and achieved clinical benefit.